Hook & thesis
MGIC Investment Corp. (MTG) presents a straightforward risk-reward today: cheap valuation, strong underlying cash generation and excess regulatory capital, and a renewed shareholder-return program. The market has pushed the shares down into oversold territory despite sequential premium growth and robust free cash flow. That combination makes this a tactical, mid-term buy into a structurally profitable mortgage insurer with clear catalysts to unlock value.
In short: buy a disciplined dip. Management has the resources and the incentive to return capital - and the stock's technical setup suggests a relatively fast mean-reversion if sentiment stabilizes.
What the company does and why the market should care
MGIC is a mortgage insurer. Its business is straightforward: insure the credit risk on mortgages that would otherwise require larger borrower down payments. Mortgage insurers make money via earned premiums and investment income, and they succeed when underwriting keeps claims manageable and capital ratios remain strong enough to allow new written business without regulatory constraints.
The market cares because MGIC's earnings and capital allocation are cyclical but measurable. The company reported new insurance written of $17.8 billion (Q2 2026) - up 8.5% year-over-year - and insurance in force of $304.8 billion, up 2.6%. Those are real, bottom-line supportive flows: underwriting revenue plus reinvestment at higher interest rates boosts earnings. On top of that, MGIC reported solid free cash flow of about $706.5 million, giving management options to fund buybacks, dividends, or shore up reserves.
Hard numbers that matter
| Metric | Value |
|---|---|
| Share price (current) | $26.37 |
| Market cap | $5.41B |
| Price / Earnings | ~7.6x |
| Price / Book | ~1.08x |
| Free cash flow (trailing) | $706.5M |
| Cash & short-term investments (reported) | ~$2.45B |
| Regulatory PMIERs excess (management commentary) | ~$2.7B |
| Short interest - days to cover (most recent) | ~4.6 days |
| Dividend (recent declaration) | $0.15 per quarter |
That table shows the core of the trade: the stock trades roughly at book value, generates healthy free cash flow, and holds significant excess regulatory capital. Low leverage (debt-to-equity ~0.13) and a current ratio north of 3.3 give the company flexibility to both write new business and return capital.
Valuation framing
MGIC's valuation is simple to interpret. At roughly $5.4 billion market cap, the stock trades at ~7.6x earnings and ~1.08x book. For an insurance business with a strong return on equity (ROE ~14%) and consistent free cash flow generation ($706M), those multiples look conservative. The company also has the levers to compress the discount to book via buybacks and dividends: on 04/23/2026 the board authorized an additional $750 million repurchase program. If executed, that authorization can meaningfully increase per-share metrics over time given the modest share count (~205 million shares outstanding).
Put another way: the business isn't growing at a breakneck pace, but it converts underwriting and investment strength into cash—and management is signaling a willingness to return that cash. That combination typically re-rates low-P/B financials over time. The current P/E well under 10x and P/B near 1x leave room for upside should the market give credit for capital returns.
Technical context and sentiment
The technical setup is supportive of a tactical long. The 14-day RSI sits in deeply oversold territory (~22), moving averages are above the current price (10/20/50-day SMAs range between $28 and $30+), and MACD shows bearish momentum but with a small histogram that can flip quickly on renewed buying. Short interest and high recent short-volume indicate there is a base of negative sentiment that can accelerate a squeeze if earnings or capital actions surprise to the upside.
Catalysts (2-5)
- Execution of the $750 million buyback program (board authorization on 04/23/2026) - active repurchases would reduce shares outstanding and lift EPS.
- Further capital returns or an increase in quarterly dividend - consistent returns would compress the discount to book.
- Continued premium growth and steady loss trends - management reported new insurance written of $17.8 billion in Q2 2026 (up 8.5% YoY); continuation of this trend supports earnings.
- Short-covering dynamics if technical momentum turns - oversold RSI and concentrated short volume can produce quick moves to the upside.
Trade plan (actionable)
Thesis: Buy MGIC on a sustained dip because valuation, capital, and buyback authorization create a time-limited opportunity for a mid-term rebound.
| Entry | Target | Stop | Position Size Guidance | Horizon |
|---|---|---|---|---|
| $26.00 | $31.00 | $24.00 | Size per risk tolerance; consider 2-4% portfolio risk max to stop. | Mid term (45 trading days) |
Rationale: At an entry of $26.00 the upside to $31.00 is ~19%, while the downside to the stop at $24.00 is ~7.7%—a favorable risk/reward for a mid-term swing. The 45-trading-day horizon gives time for buyback announcements or modest earnings/news to be priced in and allows technical mean-reversion to play out. If the position reaches $29.00 on the way up, trim partial position-size to lock in gains and move stops higher to breakeven.
Risks and counterarguments
- Credit cycle shocks: Mortgage insurers are exposed to housing-market weaknesses. A rapid deterioration in house prices or unemployment could increase claims and force reserve additions, compressing capital and earnings.
- Regulatory constraints: Changes to PMIERs or other regulatory capital requirements could limit MGIC's ability to write new business or return capital, reducing the upside of buyback-driven re-ratings.
- Execution risk on buybacks: Authorization is not the same as execution. If management delays or uses cash for other priorities, the expected per-share improvement may not materialize.
- Persistent underwriting normalization: If cure rates worsen or delinquencies increase materially, underwriting margins could compress even while investment income supports the top line.
- Macro & rate shock: Adverse moves in interest rates could negatively affect reinvestment yields or mark-to-market on investment portfolios—and heightened volatility can depress financial multiples even when fundamentals hold.
Counterargument: The conservative view says the market is correctly pricing in elevated tail risk in mortgage credit and that cheap multiples reflect structural uncertainty. If credit normalization stalls or regulatory capital deteriorates, the stock could trade lower despite buybacks. That view is reasonable: mortgage insurers sit closer to the balance-sheet cycle than many other financials, and underwriting shocks have material equity consequences.
What would change my mind
I would sell or avoid adding if one or more of the following happens: management suspends the repurchase program or pivots to significant capital preservation; reported PMIERs excess falls meaningfully from the current ~$2.7B level; new insurance written declines sequentially for multiple quarters; or the company reports a material negative surprise in loss trends requiring large reserve builds. Conversely, I would allocate more if buybacks are executed at a meaningful pace, quarterly premiums continue to grow, and management raises the dividend or announces a capital return policy with explicit targets.
Conclusion and stance
MGIC is a buy on weakness. The combination of a low multiple (P/E ~7.6; P/B ~1.08), strong free cash flow ($706M), substantial excess regulatory capital (~$2.7B), and a recently authorized $750M buyback creates a high-expected-value opportunity for a mid-term trade. My recommended plan is to enter at $26.00 with a stop at $24.00 and a target of $31.00 over the next 45 trading days, keeping position sizing conservative relative to portfolio risk. This is not a blind value trap—watch the reserving, PMIERs trends, and buyback execution closely. If those fundamentals hold or improve, the market should reward shareholders with multiple expansion and steady per-share gains.
Trade disciplined. Respect the stop. If capital execution disappoints, act quickly.